Eli Lilly Expands Neuroscience Footprint with Ataibeckley Acquisition

Dow Jones07-16 19:07

Eli Lilly is acquiring AtaiBeckley for approximately $2.8 billion initially, marking its entry into the neuroplastogen space. The deal positions Lilly to pursue a distinct approach to treating mental health conditions. AtaiBeckley's therapies aim to restore synaptic connectivity and promote new neural connections, a mechanism that contrasts with conventional antidepressants that primarily target neurotransmitter levels. Emerging research links treatment-resistant depression to a loss of synaptic plasticity in brain regions critical to mood regulation. Lilly gains a clinical-stage pipeline and a discovery program of next-generation compounds

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 16, 2026 07:07 ET (11:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment